SCHEMBL4297793

SCHEMBL4297793

CC(C)(C)OC(=O)n1nc(N)c2cc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 17/20 0.53
GSK3B P49841 10/20 0.53
MAP4K4 O95819 9/20 0.53
PRKACA P17612 9/20 0.53
CDK2 P24941 8/20 0.53
ROCK2 O75116 8/20 0.53
CLK4 Q9HAZ1 8/20 0.53
CLK2 P49760 8/20 0.53
DAPK3 O43293 7/20 0.53
PRKD3 O94806 7/20 0.53
GSK3A P49840 7/20 0.53
PRKX P51817 7/20 0.53
JAK3 P52333 7/20 0.53
CDK5 Q00535 7/20 0.53
MAP4K2 Q12851 7/20 0.53
DYRK1A Q13627 7/20 0.53
ROCK1 Q13464 6/20 0.53
AURKB Q96GD4 6/20 0.53
MKNK2 Q9HBH9 6/20 0.53
CSNK1G2 P78368 6/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285222 0.90 CDC7 (0.53) CDC7GSK3BMAP4K4PRKACACDK2
SCHEMBL3675451 0.86 CDC7 (0.58) CDC7GSK3BMAP4K4PRKACACDK2
SCHEMBL27788237 0.82 CDC7 (0.53) CDC7GSK3BMAP4K4PRKACACDK2
SCHEMBL3667784 0.80 ROCK2 (0.65) CDC7GSK3BMAP4K4PRKACACDK2
SCHEMBL3670860 0.78 DYRK3 (0.49) GSK3BROCK2CLK4CLK2GSK3A
SCHEMBL3666525 0.76 CDC7 (0.60) CDC7GSK3BMAP4K4PRKACACDK2
SCHEMBL2662495 0.74 MAP2K4 (0.45) GSK3BROCK2CLK4CLK2GSK3A
SCHEMBL22715071 0.73 MAP2K4 (0.48) GSK3BMAP4K4ROCK2CLK4CLK2
SCHEMBL29439673 0.73 MAP2K4 (0.48) GSK3BMAP4K4ROCK2CLK4CLK2
SCHEMBL4294218 0.73 CDC7 (0.65) CDC7GSK3BMAP4K4PRKACACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885GSK3B 1/4885MAP4K4 51/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885GSK3B 1/4885MAP4K4 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.